Intercept Pharmaceuticals Inc (ICPT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
51
About the Report
About the Report
Summary
Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops and commercializes treatments for non-viral, progressive liver diseases. It develops products using its proprietary bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. The company owns worldwide rights to OCA except for China, Japan and Korea, where the rights were exclusively licensed to Sumitomo Dainippon Pharma Co., Ltd., (Sumitomo Dainippon) along with an option to exclusively license OCA in certain other Asian countries. The product is also under development for the treatment of various other liver diseases. Intercept's other developmental products in pipeline include INT-767 for the treatment of fibrosis; and INT-777 for type 2 diabetes. Intercept is headquartered in New York, the US.
Intercept Pharmaceuticals Inc (ICPT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Intercept Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Intercept Pharma Raises USD 30 Million In Series C Financing 10
Partnerships 12
Intercept Pharma Extends Agreement with Target Pharma 12
Intercept Pharma Enters into Research Agreement with University of Perugia 13
Equity Offering 14
Intercept Pharma Prices Private Placement of Shares for USD100 Million 14
Intercept Pharma Prices Public Offering of Shares for USD150 Million 16
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 18
Intercept Pharma Raises USD202 Million in Public Offering of Shares 20
Intercept Pharma Completes Public Offering Of Shares For USD 192 Million 22
Intercept Pharma Completes Public Offering Of Shares For USD 65.7 Million 24
Intercept Pharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 86 Million 26
Debt Offering 28
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 28
Intercept Pharmaceuticals Inc-Key Competitors 30
Intercept Pharmaceuticals Inc-Key Employees 31
Intercept Pharmaceuticals Inc-Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 34
Financial Announcements 34
Oct 31, 2018: Intercept Pharmaceuticals reports third quarter 2018 financial results and provides business update 34
Aug 02, 2018: Intercept Pharmaceuticals reports second quarter 2018 financial results and provides business update 36
May 08, 2018: Intercept Pharmaceuticals Announces First Quarter 2018 Financial Results, Issues 2018 Ocaliva Net Sales Guidance and Provides Business Update 38
Feb 14, 2018: Intercept Pharmaceuticals Reports Net Sales Of USD 129.2 Million For The Year Ended December 31, 2017 40
Jul 31, 2017: Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update 43
May 04, 2017: Intercept Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update 45
Feb 23, 2017: Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update 47
Corporate Communications 50
Nov 27, 2017: Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51
List of Figure
List of Figures
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List of Table
List of Tables
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Intercept Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Intercept Pharma Raises USD 30 Million In Series C Financing 10
Intercept Pharma Extends Agreement with Target Pharma 12
Intercept Pharma Enters into Research Agreement with University of Perugia 13
Intercept Pharma Prices Private Placement of Shares for USD100 Million 14
Intercept Pharma Prices Public Offering of Shares for USD150 Million 16
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 18
Intercept Pharma Raises USD202 Million in Public Offering of Shares 20
Intercept Pharma Completes Public Offering Of Shares For USD 192 Million 22
Intercept Pharma Completes Public Offering Of Shares For USD 65.7 Million 24
Intercept Pharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 86 Million 26
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 28
Intercept Pharmaceuticals Inc, Key Competitors 30
Intercept Pharmaceuticals Inc, Key Employees 31
Intercept Pharmaceuticals Inc, Other Locations 32
Intercept Pharmaceuticals Inc, Subsidiaries 32
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.